Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts

Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts

Abstract Creatine transporter deficiency (CTD) is a metabolic disorder resulting in cognitive, motor, and behavioral deficits. Cyclocreatine (cCr), a creatine analog, has been explored as a therapeutic strategy for the treatment of CTD. We developed a rapid, selective, and accurate HILIC ultra‐perfo...

Full description

Bibliographic Details
Main Authors: Kirill Gorshkov, Amy Q. Wang, Wei Sun, Ethan Fisher, Marta Frigeni, Marc Singleton, Natasha Thorne, Bradley Class, Wenwei Huang, Nicola Longo, Minh‐Ha T. Do, Elizabeth A. Ottinger, Xin Xu, Wei Zheng
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Pharmacology Research & Perspectives
Subjects:
creatine
creatine transporter deficiency
cyclocreatine
HILIC UPLC–MS/MS method
phosphocreatine
phosphocyclocreatine
Online Access:https://doi.org/10.1002/prp2.525

Internet

https://doi.org/10.1002/prp2.525

Similar Items